Celltrion “The acquisition of the bio division of a US medical device company has not been finalized”
Foreign media reported on the same day that Celltrion and US medical device company Thermo Fisher Scientific are competing to acquire Baxter’s ‘Bio Pharma Solutions’ division. This division develops and commercializes medicines such as biopharmaceuticals and vaccines.
Regarding the report, a Celltrion official said, “We have reviewed the acquisition of the biopharma solution business unit, but nothing has been confirmed at this time.” “If a decision on the matter occurs, we will re-disclose it, and we will re-announce the future progress within one month,” he said.
Celltrion signed a consignment production contract with Baxter’s biopharmaceutical contract manufacturing (CMO) division in 2017 for Remsima, an autoimmune disease treatment.
